DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,592.243 B2 Wilsey (45) Date of Patent: *Mar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,592.243 B2 Wilsey (45) Date of Patent: *Mar USO09592243B2 (12) United States Patent (10) Patent No.: US 9,592.243 B2 Wilsey (45) Date of Patent: *Mar. 14, 2017 (54) MEDICAL DEVICES AND METHODS (58) Field of Classification Search COMPRISING AN ANABOLICAGENT FOR CPC ... A61L 2400/06; A61L 31/06; A61L 31/148: TREATMENT OF AN INURY A61L 31/16: A61L 26/0019; (Continued) (71) Applicant: Warsaw Orthopedic, Inc., Warsaw, IN (US) (56) References Cited (72) Inventor: Jared T. Wilsey, Memphis, TN (US) U.S. PATENT DOCUMENTS 4,624,255 A 11/1986 Schenck et al. (73) Assignee: Warsaw Orthopedic, Inc., Warsaw, IN 4,742,054 A 5, 1988 Naftchi (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 0 days. WO O3005961 A2 1, 2003 WO 2005034998 A2 4/2005 This patent is Subject to a terminal dis WO 2007OO5177 A1 1, 2007 claimer. (21) Appl. No.: 14/085,444 OTHER PUBLICATIONS Chhipa et al “Formulation Optimization of Sustained Release (22) Filed: Nov. 20, 2013 Pellets of Itopride Hydrochloride using Different Polymers,” Jour (65) Prior Publication Data nal of Pharmacy Research 2009 2(8) 1404-1408).* (Continued) US 2014/0107088 A1 Apr. 17, 2014 Primary Examiner — Suzanne Ziska Related U.S. Application Data (63) Continuation-in-part of application No. 13/093,479, (57) ABSTRACT filed on Apr. 25, 2011. Improved medical devices and methods are provided com prising an anabolic agent for healing an injury. These (51) Int. Cl. improved medical devices and methods can enhance healing A6 IK3I/58 (2006.01) in injuries from traumatic soft tissue injury, Surgical injuries, A6 IK 47/34 (2006.01) burn, traumatic brain injuries, musculotendinous injuries, musculoskeletal conditions, bone injury or other injuries or (Continued) maladies, which can be chronic or non-chronic in origin. In (52) U.S. Cl. Some embodiments, the medical device comprises a drug CPC .............. A6 IK3I/58 (2013.01); A61K 38/27 depot that releases the anabolic agent over at least 2 days to (2013.01); A61K 38/28 (2013.01); A61K 38/30 enhance healing of an injury. (2013.01); (Continued) 8 Claims, 1 Drawing Sheet low lose of local Estatiot Systeic Starozoic Accelerates foici tieairag k-k's 3: r to Nothing Applied Conto: x Starozoic ing or Ray (3. {3, 5 fig Rays 2, 3, and 8 Rart 3ieties 8 foci: Starozoic-r&aised Arias US 9,592.243 B2 Page 2 (51) Int. Cl. 2002/0009454 A1 1/2002 Boone et al. 2002/0090398 A1 7, 2002 Dunn et al. A6IL 26/00 (2006.01) 2002/O122771 A1 9, 2002 Holland et al. A6 IK 38/27 (2006.01) 2002/0127269 A1 9/2002 Waring et al. A6 IK 38/28 (2006.01) 2003/0022927 A1 1/2003 Jeon et al. A6 IK 38/30 (2006.01) 2003.0185873 A1 10, 2003 Chasin et al. 2003/0203044 A1 10, 2003 Moravec A6IL 3L/06 (2006.01) 2003/0204191 A1 10, 2003 Sater et al. A6IL 3L/4 (2006.01) 2003,0224033 A1 12/2003 Li et al. A6IL 3L/6 (2006.01) 2004f0072799 A1 4, 2004 Li et al. (52) U.S. Cl 2004/0082540 A1 4/2004 Hermida Ochoa AV e. we 2004/0097468 A1 5, 2004 Sunil CPC ............ A61K 47/34 (2013.01); A61L 26/009 2004.01098.93 A1 6/2004 Chen et al. (2013.01); A61L 26/0019 (2013.01); A61L 2004/0214793 A1 10, 2004 Hermida Ochoa 2005/0059744 A1 3/2005 Donello et al. 26/0066 (2013.01); A61L 31/06 (2013.01); 2005/012965.6 A1 6/2005 Goupil et al. A61L 3 1/148 (2013.01); A61L 3 1/16 2005. O142163 A1 6/2005 Hunter et al. (2013.01); A61L 2300/222 (2013.01); A61 L 2005/0175709 A1 8/2005 Baty, III et al. 2300/414 (2013.01); A61 L 2300/43 (2013.01); 2005, 0186261 A1 8, 2005 Avelar et al. 2005/O197293 A1 9, 2005 Mellis et al. A61 L 2300/604 (2013.01); A61 L 2400/06 2005/0222684 A1 10, 2005 Ferree (2013.01) 2005/0287218 A1 12/2005 Chaouk et al. (58) Field of Classification Search 2005/0288789 A1 12/2005 Chaouk et al. CPC ............... A61L 26/009; A61L 26/0066; A61L 2006, OO74422 A1 4/2006 Story et al. 2006/0106361 A1 5, 2006 Muni et al. 2300/222: A61L 2300/414; A61L 2006/0147488 A1* 7/2006 Wohlert ........................ 424/423 2300/43; A61L 2300/604; A61K 38/27; 2006, O148903 A1 7/2006 Burch et al. A61K 38/28: A61K 38/30; A61K 47/34: 2006, O183786 A1 8/2006 Wang A61K 31/58; C08L 67/04 2006, O189944 A1 8/2006 Campbell et al. See application file for complete search history. 2006/0228391 A1 10/2006 Seyedin et al. 2007,0004790 A1 1/2007 Chow et al. 2007/0066568 A1 3/2007 Dalton et al. ................... 514.80 (56) References Cited 2007/0093.907 A1 4/2007 Goupil et al. 2007. O150061 A1 6, 2007 Trieu U.S. PATENT DOCUMENTS 2007. O156180 A1 7/2007 Jaax et al. 2007/O185497 A1 8, 2007 Cauthen et al. E. A 29: i. 2007/0202074 A1 8/2007 Shalaby 5.571882. A 1/1996 R SO 2007/0243225 A1 10/2007 McKay - J. f etter h 2007/0243228 A1 10/2007 McKay Sgt. A S. Yagh Jr. 2007/0248639 A1 10/2007 Demopulos et al. W unn et al. 2007,0253994 A1 11/2007 Hildebrand 5,759,583 A 6,f 1998 Iwamotob et al. 2008, 0021074 A1 1/2008 Cartt 5,868,789 A &E s Ital 2008/0085263 A1 4/2008 Krister et al. 5,942,241 A 8/1999 Chasin et al. 2008/0091207 A1 4/2008 Truckai et al. 6,069,129 A 5/2000 Sandberg et al. 2008.OO97229 A1 4/2008 Roy et al. 6,179,862 B1 1/2001 Sawhney 2008/0269717 A1 10, 2008 Crandall et al. 6,248.345 B1 6/2001 Goldenheim et al. 2009/0020076 A1 1/2009 Ghiraldi 6,287,588 B1 9, 2001 Shih et al. 2009/0048678 A1 2/2009 Saal et al. 6,326,020 B1 12/2001 Kohane et al. 2009.0143333 A1 6/2009 Palefsky et al. 6,331,311 B1 12/2001 Brodbeck et al. 2009/0202645 A1 8, 2009 Predieri 6,428,804 B1 8, 2002 Suzuki et al. 2009, 0222096 A1 9, 2009 Trieu 6,461,631 B1 10/2002 Dunn et al. 2009/0246 123 A1 10, 2009 Zanella et al. 6,524,607 B1 2/2003 Goldenheim et al. 2009,0263319 A1 10, 2009 Wohabrebbi et al. 6,534,081 B2 3/2003 Goldenheim et al. 2009,0263.489 A1 10, 2009 Zanella 6,589,549 B2 7/2003 Shih et al. 2009,0264489 A1 10, 2009 Hildebrand et al. 6,616,946 B1 9, 2003 Meier et al. 2009/0275913 A1 11/2009 Trieu 6,630, 155 B1 10/2003 Chandrashekar et al. 6,632.457 B1 10/2003 Sawhney 2010/0239632 A1 9, 2010 Walsh 6,652,883 B2 11/2003 Goupil et al. 6,676,971 B2 1/2004 Goupil et al. OTHER PUBLICATIONS 6,710,126 B1 3, 2004 Hirt et al. 6,723,741 B2 4/2004 Jeon et al. American Burn Association, Burn Incidence and Treatment in the 6,723,814 B2 4/2004 Meier et al. 6,756,058 B2 6, 2004 Brubaker et al. United States: 2011 Fact Sheet, 1 pg. 6,773,714 B2 8, 2004 Dunn et al. QLT, Inc., Atrigel, Drug Delivery Platform, www.qltinc.com. Fort 6,921,541 B2 7/2005 Chasin et al. Collins, CO, U.S., Jul. 2006, 2 pgs. 6,974.462 B2 12/2005 Sater Lynda Cole, RN and Caroline Nesbitt, RN, A Three-Year 7,070,809 B2 7/2006 Goupil et al. Multiphase Pressure Ulcer Prevalence/Incidence Study in a 7,144,412 B2 12/2006 Wolfe et al. Regional Referral Hospital, vol. 57, Issue 1, Jan. 2011, pp. 1-5. 7,166.570 B2 1/2007 Hunter et al. Robert H. Demling, MD., Oxandrolone, an anabolic steroid, 7,220.281 B2 5/2007 Lambrecht et al. enhances the healing of a cutaneous wound in the rat, Wound Repair 7,229,441 B2 6, 2007 Trieu et al. and Regeneration, Mar.-Apr. 2000, Boston, MA pp. 97-102. 7,235,043 B2 6, 2007 Gellman et al. Robert H. Demling. MD. The Role of Anabolic Hormones for 7,287,983 B2 10/2007 Ilan O . Lemling, MD, 7,318,840 B2 1/2008 McKay Wound Healing in Catabolic States, Journal of Burns and Wounds, 7,361,168 B2 4/2008 Makower et al. Brigham & Women's Hospital, Boston, MA, and Harvard Medical 7,367,978 B2 5/2008 Drewry et al. School, Boston, MA. 2005, vol. 4, pp. 46-62. 7,829, 110 B2 11/2010 Wohlert William H. Eaglstein, M.D., Patricia Mertz, B.A. and Oscar M. 8,470,360 B2 * 6/2013 McKay ......................... 424/426 Alvarez, Ph.D., Effect of Topically Applied Agents on Healing US 9,592.243 B2 Page 3 (56) References Cited OTHER PUBLICATIONS Wounds, Dept. of Dermatology, Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, and Cornell Univ. Mecial Center, New York, NY, Jul.-Sep. 1984, vol. 2, No. 3, pp. 112-115. Helena Cristina Franciso Pereira Da Silva, Rodrigo Cecanho, Cephalometric changes produced by locally applied anabolic Ste roid in Wistar rats, Archives of Oral Biology 54 (2009) pp. 389-395. Daniel P. Moore, M.D., Helping your patients with spasticity reach maximal function, vol.
Load more

Recommended publications
  • Prnu-BICALUTAMIDE
    PRODUCT MONOGRAPH PrNU-BICALUTAMIDE Bicalutamide Tablets, 50 mg Non-Steroidal Antiandrogen NU-PHARM INC. DATE OF PREPARATION: 50 Mural Street, Units 1 & 2 October 16, 2009 Richmond Hill, Ontario L4B 1E4 Control#: 133521 Page 1 of 27 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS....................................................................................... 4 ADVERSE REACTIONS......................................................................................................... 5 DRUG INTERACTIONS ......................................................................................................... 9 DOSAGE AND ADMINISTRATION ................................................................................... 10 OVERDOSAGE...................................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 10 STORAGE AND STABILITY............................................................................................... 11 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • A20-0767), As Follows:​
    05/05/20 03:02 pm ​ HOUSE RESEARCH JD/RK H2711A8​ 1.1 .................... moves to amend H.F. No. 2711, the delete everything amendment​ 1.2 (A20-0767), as follows:​ 1.3 Page 21, delete section 1​ 1.4 Page 36, delete section 2​ 1.5 Page 40, delete section 3 and insert:​ 1.6 "Section 1. Minnesota Statutes 2018, section 152.02, subdivision 2, is amended to read:​ 1.7 Subd. 2. Schedule I. (a) Schedule I consists of the substances listed in this subdivision.​ 1.8 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the​ 1.9 following substances, including their analogs, isomers, esters, ethers, salts, and salts of​ 1.10 isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,​ 1.11 and salts is possible:​ 1.12 (1) acetylmethadol;​ 1.13 (2) allylprodine;​ 1.14 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl​ 1.15 acetate);​ 1.16 (4) alphameprodine;​ 1.17 (5) alphamethadol;​ 1.18 (6) alpha-methylfentanyl benzethidine;​ 1.19 (7) betacetylmethadol;​ 1.20 (8) betameprodine;​ 1.21 (9) betamethadol;​ Section 1.​ 1​ 05/05/20 03:02 pm ​ HOUSE RESEARCH JD/RK H2711A8​ 2.1 (10) betaprodine;​ 2.2 (11) clonitazene;​ 2.3 (12) dextromoramide;​ 2.4 (13) diampromide;​ 2.5 (14) diethyliambutene;​ 2.6 (15) difenoxin;​ 2.7 (16) dimenoxadol;​ 2.8 (17) dimepheptanol;​ 2.9 (18) dimethyliambutene;​ 2.10 (19) dioxaphetyl butyrate;​ 2.11 (20) dipipanone;​ 2.12 (21) ethylmethylthiambutene;​ 2.13 (22) etonitazene;​ 2.14 (23) etoxeridine;​ 2.15 (24) furethidine;​
    [Show full text]
  • A New Highly Specific and Robust Yeast Androgen Bioassay for the Detection of Agonists and Antagonists
    Anal Bioanal Chem (2007) 389:1549–1558 DOI 10.1007/s00216-007-1559-6 ORIGINAL PAPER A new highly specific and robust yeast androgen bioassay for the detection of agonists and antagonists Toine F. H. Bovee & Richard J. R. Helsdingen & Astrid R. M. Hamers & Majorie B. M. van Duursen & Michel W. F. Nielen & Ron L. A. P. Hoogenboom Received: 27 April 2007 /Revised: 3 July 2007 /Accepted: 15 August 2007 / Published online: 12 September 2007 # Springer-Verlag 2007 Abstract Public concern about the presence of natural and very specific and also suited to detect compounds that have anthropogenic compounds which affect human health by an antiandrogenic mode of action. modulating normal endocrine functions is continuously growing. Fast and simple high-throughput screening methods Keywords Antagonists . Brominated flame retardants . for the detection of hormone activities are thus indispens- Crosstalk . Metabolism . Receptor . Saccharomyces able. During the last two decades, a panel of different in vitro cerevisiae assays has been developed, mainly for compounds with an estrogenic mode of action. Here we describe the develop- ment of an androgen transcription activation assay that is Introduction easy to use in routine screening. Recombinant yeast cells were constructed that express the human androgen receptor There is concern that chemicals in our food, water, and and yeast enhanced green fluorescent protein (yEGFP), the environment affect human health by disrupting normal latter in response to androgens. Compared with other endocrine function, possibly leading to reproductive failure reporters, the yEGFP reporter protein is very convenient in humans and tumors in sensitive tissues [1, 2]. This because it is directly measurable in intact living cells, i.e., relates to chemicals with previously unknown hormonal cell wall disruption and the addition of a substrate are not properties, like certain pesticides and plasticizers, but also needed.
    [Show full text]
  • Steroids and Other Appearance and Performance Enhancing Drugs (Apeds) Research Report
    Research Report Revised Febrero 2018 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Table of Contents Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Introduction What are the different types of APEDs? What is the history of anabolic steroid use? Who uses anabolic steroids? Why are anabolic steroids misused? How are anabolic steroids used? What are the side effects of anabolic steroid misuse? How does anabolic steroid misuse affect behavior? What are the risks of anabolic steroid use in teens? How do anabolic steroids work in the brain? Are anabolic steroids addictive? How are anabolic steroids tested in athletes? What can be done to prevent steroid misuse? What treatments are effective for anabolic steroid misuse? Where can I get further information about steroids? References Page 1 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Esta publicación está disponible para su uso y puede ser reproducida, en su totalidad, sin pedir autorización al NIDA. Se agradece la citación de la fuente, de la siguiente manera: Fuente: Instituto Nacional sobre el Abuso de Drogas; Institutos Nacionales de la Salud; Departamento de Salud y Servicios Humanos de los Estados Unidos. Introduction Appearance and performance enhancing drugs (APEDs) are most often used by males to improve appearance by building muscle mass or to enhance athletic performance. Although they may directly and indirectly have effects on a user’s mood, they do not produce a euphoric high, which makes APEDs distinct from other drugs such as cocaine, heroin, and marijuana. However, users may develop a substance use disorder, defined as continued use despite adverse consequences.
    [Show full text]
  • Supraphysiological Doses of Performance Enhancing Anabolic-Androgenic Steroids Exert Direct Toxic Effects on Neuron-Like Cells
    ORIGINAL RESEARCH ARTICLE published: 09 May 2013 CELLULAR NEUROSCIENCE doi: 10.3389/fncel.2013.00069 Supraphysiological doses of performance enhancing anabolic-androgenic steroids exert direct toxic effects on neuron-like cells John R. Basile1,2, Nada O. Binmadi 1,3, Hua Zhou1, Ying-Hua Yang1, Antonio Paoli 4 and Patrizia Proia1,5* 1 Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, Baltimore, MD, USA 2 Marlene and Stuart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA 3 Department of Oral Basic and Clinical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia 4 Department of Biomedical Sciences, University of Padova, Padova, Italy 5 Department of Sports Science (DISMOT), University of Palermo, Palermo, Italy Edited by: Anabolic-androgenic steroids (AAS) are lipophilic hormones often taken in excessive Chao Deng, University of quantities by athletes and bodybuilders to enhance performance and increase muscle Wollongong, Australia mass. AAS exert well known toxic effects on specific cell and tissue types and organ Reviewed by: systems. The attention that androgen abuse has received lately should be used as an Agata Copani, University of Catania, Italy opportunity to educate both athletes and the general population regarding their adverse Aram Megighian, University of effects. Among numerous commercially available steroid hormones, very few have been Padua, Italy specifically tested for direct neurotoxicity. We evaluated the effects of supraphysiological *Correspondence: doses of methandienone and 17-α-methyltestosterone on sympathetic-like neuron cells. Patrizia Proia, Department of Sports Vitality and apoptotic effects were analyzed, and immunofluorescence staining and Science (DISMOT), University of Palermo, Via Eleonora Duse 2, western blot performed.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]